Syncom Formulations (India) Limited

524470

INE312C01025

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:47:58 07/06/2024 pm IST			5-day change	1st Jan Change
12.03 ^INR	-0.17%		+0.42%	-20.01%

17/05	Syncom Formulations Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI
17/05	Syncom Formulations Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI

Syncom Formulations India Ltd Announces Resignation of Praniti Porwal as Company Secretary and Compliance Officer

October 31, 2015 at 04:09 pm IST

Syncom Formulations India Ltd. announced that Ms. Praniti Porwal, Company Secretary and Compliance Officer of the company has resigned from the office of the same with effect from October 31, 2015.

Latest news about Syncom Formulations (India) Limited

Syncom Formulations Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	17/05	CI
Syncom Formulations Limited Reports Earnings Results for the Full Year Ended March 31, 2024	17/05	CI
Syncom Formulations Limited Announces Board Changes	29/03	CI
Syncom Formulations Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14/02	CI
Syncom Formulations Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	08/11	CI
Syncom Formulations Begins Commercial Production at Expanded Plant in Pithampur, India	22/23/22	MT
Syncom Formulations Limited Commences Commercial Production	21/23/21	CI
Syncom Formulations Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/23/14	CI
Syncom Formulations Limited Announces Commercial Production Starts from 30 June 2023	01/23/01	CI
Syncom Formulations Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	29/23/29	CI
Syncom Formulations Limited Reports Earnings Results for the Full Year Ended March 31, 2023	29/23/29	CI
Syncom Formulations Limited Announces Executive Changes	02/23/02	CI
Syncom Formulations Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	13/23/13	CI
Syncom Formulations Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/22/14	CI
Syncom Formulations Limited Approves the Declaration of Dividend for the Financial Year Ended 31 March 2022	20/22/20	CI
Syncom Formulations Sees Delay in Completion of Expansion Project	16/22/16	MT
Syncom Formulations Limited Announces Updates on its Project for Expansion Cum Modernisation of Existing Plant at Pithampur	15/22/15	CI
Syncom Formulations Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	13/22/13	CI
Syncom Formulations Limited Appoints Ruchi Jindal as an Additional Director	28/22/28	CI
Syncom Formulations Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/22/14	CI
Syncom Formulations Limited Announces Executive Changes	13/21/13	CI
Syncom Formulations Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	13/21/13	CI
Syncom Formulations India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	30/21/30	CI
Syncom Formulations Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	12/21/12	CI
Syncom Formulations Limited announced that it has received INR 100.787496 million in funding	25/21/25	CI

Chart Syncom Formulations (India) Limited

Duration

Period

Chart Syncom Formulations (India) Limited

More charts

Syncom Formulations (India) Limited is an India-based company that is engaged in the pharmaceutical business. The Company is engaged in the manufacturing and dealing in pharmaceutical drugs and formulations, and trading of commodities. It is also engaged in the renting of properties. It manufactures and markets a range of pharmaceutical formulations in various dosage forms, such as tablets, capsules, liquids orals, liquid vials and ampoule injections and dry powder injections, ophthalmic preparations, dry syrups and suspensions, ointments, creams, gel, ORS and jelly. The Company's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Cefuroxime For Injection USP 750 mg and Gentamicin Injection BP 40 mg.

Sector

Pharmaceuticals

Calendar

14/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SYNCOM FORMULATIONS (INDIA) LIMITED	-20.01%	135M
ELI LILLY AND COMPANY	+45.82%	765B
NOVO NORDISK A/S	+40.95%	632B
JOHNSON & JOHNSON	-6.16%	354B
MERCK & CO., INC.	+19.86%	331B
ABBVIE INC.	+9.32%	299B
ASTRAZENECA PLC	+18.45%	248B
ROCHE HOLDING AG	-0.78%	219B
NOVARTIS AG	+11.88%	216B
AMGEN INC.	+5.90%	164B